Suppr超能文献

儿童医用大麻

Medical Cannabis in Children.

作者信息

Aran Adi, Cayam-Rand Dalit

机构信息

Neuropediatric Unit, Shaare Zedek Medical Center, Jerusalem, Israel.

出版信息

Rambam Maimonides Med J. 2020 Jan 30;11(1):e0003. doi: 10.5041/RMMJ.10386.

Abstract

The use of medical cannabis in children is rapidly growing. While robust evidence currently exists only for pure cannabidiol (CBD) to treat specific types of refractory epilepsy, in most cases, artisanal strains of CBD-rich medical cannabis are being used to treat children with various types of refractory epilepsy or irritability associated with autism spectrum disorder (ASD). Other common pediatric disorders that are being considered for cannabis treatment are Tourette syndrome and spasticity. As recreational cannabis use during youth is associated with serious adverse events and medical cannabis use is believed to have a relatively high placebo effect, decisions to use medical cannabis during childhood and adolescence should be made with caution and based on evidence. This review summarizes the current evidence for safety, tolerability, and efficacy of medical cannabis in children with epilepsy and in children with ASD. The main risks associated with use of Δ9-tetrahydrocannabinol (THC) and CBD in the pediatric population are described, as well as the debate regarding the use of whole-plant extract to retain a possible "entourage effect" as opposed to pure cannabinoids that are more standardized and reproducible.

摘要

医用大麻在儿童中的使用正在迅速增加。虽然目前只有关于纯大麻二酚(CBD)治疗特定类型难治性癫痫的有力证据,但在大多数情况下,富含CBD的手工制作的医用大麻品种正被用于治疗患有各种类型难治性癫痫或与自闭症谱系障碍(ASD)相关的易怒症状的儿童。正在考虑用大麻治疗的其他常见儿科疾病是抽动秽语综合征和痉挛。由于青少年使用娱乐性大麻与严重不良事件相关,且医用大麻的使用被认为具有相对较高的安慰剂效应,因此在儿童期和青春期使用医用大麻的决定应谨慎做出并基于证据。本综述总结了目前关于医用大麻在癫痫儿童和自闭症谱系障碍儿童中的安全性、耐受性和有效性的证据。描述了儿科人群中使用Δ9-四氢大麻酚(THC)和CBD相关的主要风险,以及关于使用全植物提取物以保留可能的“协同效应”与使用更标准化和可重复的纯大麻素的争论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e737/7000154/4ad13452c520/rmmj-11-1-e0003-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验